Literature DB >> 22596201

Antisense therapeutics: New ways to nudge splicing.

Ian Eperon.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22596201     DOI： 10.1038/nchembio.968

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN： 1552-4450            Impact factor:   15.040


× No keyword cloud information.
  9 in total

Review 1.  Genetic therapies for RNA mis-splicing diseases.

Authors:  Suzan M Hammond; Matthew J A Wood
Journal:  Trends Genet       Date:  2011-04-15       Impact factor: 11.639

2.  Systemic administration of PRO051 in Duchenne's muscular dystrophy.

Authors:  Nathalie M Goemans; Mar Tulinius; Johanna T van den Akker; Brigitte E Burm; Peter F Ekhart; Niki Heuvelmans; Tjadine Holling; Anneke A Janson; Gerard J Platenburg; Jessica A Sipkens; J M Ad Sitsen; Annemieke Aartsma-Rus; Gert-Jan B van Ommen; Gunnar Buyse; Niklas Darin; Jan J Verschuuren; Giles V Campion; Sjef J de Kimpe; Judith C van Deutekom
Journal:  N Engl J Med       Date:  2011-03-23       Impact factor: 91.245

3.  Exonic sequences provide better targets for antisense oligonucleotides than splice site sequences in the modulation of Duchenne muscular dystrophy splicing.

Authors:  Annemieke Aartsma-Rus; Hellen Houlleberghs; Judith C T van Deutekom; Gert-Jan B van Ommen; Peter A C 't Hoen
Journal:  Oligonucleotides       Date:  2010-04

4.  Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.

Authors:  Sebahattin Cirak; Virginia Arechavala-Gomeza; Michela Guglieri; Lucy Feng; Silvia Torelli; Karen Anthony; Stephen Abbs; Maria Elena Garralda; John Bourke; Dominic J Wells; George Dickson; Matthew J A Wood; Steve D Wilton; Volker Straub; Ryszard Kole; Stephen B Shrewsbury; Caroline Sewry; Jennifer E Morgan; Kate Bushby; Francesco Muntoni
Journal:  Lancet       Date:  2011-07-23       Impact factor: 79.321

5.  Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts.

Authors:  Leigh A Skordis; Matthew G Dunckley; Baigong Yue; Ian C Eperon; Francesco Muntoni
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-17       Impact factor: 11.205

6.  Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice.

Authors:  Yimin Hua; Timothy A Vickers; Hazeem L Okunola; C Frank Bennett; Adrian R Krainer
Journal:  Am J Hum Genet       Date:  2008-03-27       Impact factor: 11.025

7.  Reprogramming alternative pre-messenger RNA splicing through the use of protein-binding antisense oligonucleotides.

Authors:  Jonathan Villemaire; Isabelle Dion; Sherif Abou Elela; Benoit Chabot
Journal:  J Biol Chem       Date:  2003-09-30       Impact factor: 5.157

8.  Synthetic oligonucleotides recruit ILF2/3 to RNA transcripts to modulate splicing.

Authors:  Frank Rigo; Yimin Hua; Seung J Chun; Thazha P Prakash; Adrian R Krainer; C Frank Bennett
Journal:  Nat Chem Biol       Date:  2012-04-15       Impact factor: 15.040

9.  Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model.

Authors:  Yimin Hua; Kentaro Sahashi; Frank Rigo; Gene Hung; Guy Horev; C Frank Bennett; Adrian R Krainer
Journal:  Nature       Date:  2011-10-05       Impact factor: 49.962
  9 in total
  1 in total

1.  A targeted oligonucleotide enhancer of SMN2 exon 7 splicing forms competing quadruplex and protein complexes in functional conditions.

Authors:  Lindsay D Smith; Rachel L Dickinson; Christian M Lucas; Alex Cousins; Alexey A Malygin; Carika Weldon; Andrew J Perrett; Andrew R Bottrill; Mark S Searle; Glenn A Burley; Ian C Eperon
Journal:  Cell Rep       Date:  2014-09-25       Impact factor: 9.423
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.